(Q44462077)

3 December 2017

title

The economic evaluation of pharmacotherapies for Parkinson's disease (English)

1 reference

3 December 2017

0 references

1 reference

1

1 reference

3 December 2017

M Barbeau

2

1 reference

3 December 2017

M Guttman

series ordinal

3

1 reference

3 December 2017

J-F Baladi

series ordinal

4

1 reference

3 December 2017

publication date

1 June 2003

1 reference

3 December 2017

number of pages

7

1 reference

Parkinsonism and Related Disorders

inferred from page(s)

published in

1 reference

3 December 2017

volume

9

1 reference

3 December 2017

issue

5

1 reference

3 December 2017

page(s)

301-307

1 reference

Impact of Parkinson's disease and its pharmacologic treatment on quality of life and economic outcomes.

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900116-5

7 January 2021

Parkinson's disease. First of two parts

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900116-5

7 January 2021

Cost-effectiveness analysis in Parkinson's disease: determining the value of interventions

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900116-5

7 January 2021

The economic impact of Parkinson's disease. An estimation based on a 3-month prospective analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900116-5

7 January 2021

The burden of Parkinson's disease on society, family, and the individual.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900116-5

7 January 2021

The Impact of Parkinson??s Disease on Health Status, Health Expenditures, and Productivity

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900116-5

7 January 2021

Cost of illness and disease severity in a cohort of French patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900116-5

7 January 2021

Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900116-5

7 January 2021

Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900116-5

7 January 2021

Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900116-5

7 January 2021

The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900116-5

7 January 2021

Costs and cost-minimisation analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900116-5

7 January 2021

Cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900116-5

7 January 2021

Cost-utility analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900116-5

7 January 2021

Utilities and quality-adjusted life years

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900116-5

7 January 2021

Cost-benefit analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900116-5

7 January 2021

Cost-per-QALY league tables: their role in pharmacoeconomic analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900116-5

7 January 2021

Trials and tribulations. Emerging issues in designing economic evaluations alongside clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900116-5

7 January 2021

Modelling in economic evaluation: an unavoidable fact of life

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900116-5

7 January 2021

An introduction to Markov modelling for economic evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900116-5

7 January 2021

Patient preferences and utilities for 'off-time' outcomes in the treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900116-5

7 January 2021

Cost-effectiveness analysis of entacapone in Parkinson's disease: a Markov process analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900116-5

7 January 2021

Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900116-5

7 January 2021

Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900116-5

7 January 2021

10.1016/S1353-8020(02)00116-5

Identifiers

DOI

1 reference

3 December 2017

1 reference